Meet members of the ITF Therapeutics team to learn more about their organization and next steps to support the availability of DUVYZAT.
CureDuchenne Community Webinar Update with ITF Therapeutics: Introducing DUVYZAT™ (givinostat) Meet members of the ITF Therapeutics team to learn more about their organization and the next steps to support the […]
Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that the results of its research into developing an accurate and reproducible method for the measurement of dystrophin in patients with Duchenne muscular dystrophy (DMD) and Becker’s muscular dystrophy (BMD) have been published in the online peer reviewed journal PLOS ONE (https://bit.ly/ZJ8ShM).
Napa in Newport Celebrates a Decade of Impact and
Raises More Than $1.35M for CureDuchenne
If you have a desire to drive with Duchenne muscular dystrophy or be a passenger in a wheelchair-accessible vehicle, there are plenty of opportunities to make that dream a reality.
NEWPORT BEACH Calif., March 8, 2024 – Marking a significant milestone, Napa in Newport benefiting CureDuchenne will commemorate its 10th anniversary on April 20, 2024, at the luxurious Pendry Newport Beach. Esteemed for its unparalleled selection of Napa Valley’s finest wines, this year’s gala is a celebration of a decade-long journey of philanthropy, community, and exquisite wine. The gala showcases a Grand Tasting, dining tables hosted by vintners, a handcrafted dinner with carefully selected wine pairings, and extraordinary auction items including rare wines, luxurious vacations, and one-of-a-kind experiences. The evening is set to be more intimate than ever before, with limited attendance and new, luxurious weekend ticket packages that include hotel accommodations and amenities.
By Jennifer Wallace, PT and Doug Levine, PT Introduction Duchenne muscular dystrophy (DMD) is a neuromuscular disorder that affects an estimated 1 in 5,000 live male births and is largely […]
CureDuchenne Welcomes Patricia Brown as Senior Director of Community Engagement
The U.S. FDA announced today its decision to approve AGAMREE (vamorolone), a new steroid for individuals with Duchenne muscular dystrophy 2 years or older. This approval comes largely based on […]
